Right to Try Gives Terminal Patients Access to Potentially Life-Saving Treatments Without FDA Permission
An interview with Christina Sandefur of the Goldwater Institute, which was instrumental in passing the new federal law.
In May of 2018, President Donald Trump signed a new law allowing patients with life-threatening conditions to access experimental medications without obtaining FDA approval.
In our latest podcast, Reason's Zach Weissmueller sits down with Christina Sandefur, executive vice president of the Arizona-based Goldwater Institute, which played a key role in getting the law passed in 41 states before it arrived on the president's desk.
For more on the topic, watch Weissmueller's video documentary on subject. In this conversation, he and Sandefur delve deeper into the details of the new Right to Try law, why it matters, how it got it passed, some criticisms of the legislation, and what more needs to be done to bring down prescription drug costs and spur innovation.
Audio production by Ian Keyser.
